|21st December 2020||Gillian C Ivers Read||829||Open or private sale||$5.68||$4,708.72|
|21st December 2020||Gillian C Ivers Read||1,875||Exercise of derivative||$0.00|
|21st December 2020||Lindsey Rolfe||1,728||Open or private sale||$5.68||$9,815.04|
|21st December 2020||Lindsey Rolfe||3,438||Exercise of derivative||$0.00|
|15th December 2020||Lindsey Rolfe||14,153||Payment by withholding||$5.11||$72,321.83|
|15th December 2020||Lindsey Rolfe||17,241||Exercise of derivative||$3.28||$56,550.48|
|3rd December 2020||Lindsey Rolfe||625||Exercise of derivative||$0.00|
|3rd December 2020||Lindsey Rolfe||315||Open or private sale||$4.89||$1,540.35|
|3rd December 2020||Gillian C Ivers Read||277||Open or private sale||$4.89||$1,354.53|
|3rd December 2020||Gillian C Ivers Read||625||Exercise of derivative||$0.00|
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Clovis Oncology, Inc. is a commercial stage biotechnology company. It engages in the acquisition, development, and commercialization of cancer treatments in the United States, Europe, and other markets.